Last reviewed · How we verify
everolimus dose escalation
everolimus dose escalation is a Small molecule drug developed by Radboud University Medical Center. It is currently FDA-approved.
At a glance
| Generic name | everolimus dose escalation |
|---|---|
| Sponsor | Radboud University Medical Center |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies (PHASE1)
- Everolimus in CDK12-Deficient Metastatic Colorectal Cancer (EVER-RECODE) (PHASE1, PHASE2)
- Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer. (PHASE1)
- Sapu003 in Advanced mTOR-sensitive Solid Tumors (PHASE1)
- A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread (PHASE1)
- Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy (PHASE3)
- Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer (PHASE1)
- Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- everolimus dose escalation CI brief — competitive landscape report
- everolimus dose escalation updates RSS · CI watch RSS
- Radboud University Medical Center portfolio CI
Frequently asked questions about everolimus dose escalation
What is everolimus dose escalation?
everolimus dose escalation is a Small molecule drug developed by Radboud University Medical Center.
Who makes everolimus dose escalation?
everolimus dose escalation is developed and marketed by Radboud University Medical Center (see full Radboud University Medical Center pipeline at /company/radboud-university-medical-center).
What development phase is everolimus dose escalation in?
everolimus dose escalation is FDA-approved (marketed).
Related
- Manufacturer: Radboud University Medical Center — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing